A recent study found the drug combination lenalidomide + rituximab is a durable, effective and safe alternative to the standard regimen combining rituximab and chemotherapy.
The lone volunteer in a unique study involving a gene-editing technique has died, and those behind the trial are now trying to figure out what killed him.